On August 24, 2026 Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, reported that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL"), with Seoul St. Mary’s Hospital identified as the lead clinical site.
Under the engagement, Synex will provide clinical research services pursuant to a milestone-based program, with payments linked to key clinical development milestones, including patient enrollment, database lock and completion of the clinical study report.
"Engaging Synex is another important step in moving IBC101 from regulatory authorization toward clinical execution," said Chris Kim, Chief Executive Officer of Liminatus. "Synex brings extensive experience supporting pharmaceutical clinical development in Korea, and we believe its local regulatory and clinical capabilities will be valuable as we advance the IBC101 Phase 1/2a program."
IBC101 is an autologous CD19xCD22 bivalent CAR-T cell therapy designed for relapsed or refractory B-cell malignancies. The candidate utilizes an OR-gate approach intended to recognize malignant B cells expressing either CD19 or CD22. By targeting two established B-cell antigens, IBC101 is designed to broaden antigen coverage and potentially address antigen escape and tumor heterogeneity, two mechanisms associated with relapse following single-antigen CAR-T therapy.
The IBC101 program further expands Liminatus’ oncology development portfolio beyond its IBA101 CD47 checkpoint inhibitor program and establishes an additional clinical-stage development pathway focused on hematologic malignancies.
"Following the expansion of our oncology portfolio, our focus is increasingly shifting toward execution across our development programs," added Mr. Kim. "The Synex engagement provides clinical infrastructure in Korea to support the next stage of IBC101’s development, and we look forward to progressing the program toward patient enrollment."
About IBC101
IBC101 is an investigational autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for the treatment of relapsed or refractory B-cell malignancies. The therapy is designed as an OR-gate CAR-T system capable of recognizing tumor cells expressing either CD19 or CD22, with the goal of expanding antigen coverage and reducing the potential for antigen escape associated with single-target CAR-T therapies. IBC101 has received authorization from the MFDS for a Phase 1/2a clinical study in relapsed or refractory DLBCL.
(Press release, Liminatus Pharma, AUG 24, 2026, View Source [SID1234670307])